Veryan has developed a three-dimensional stent technology, BioMimics 3D™, which improves upon the biomechanical and flow characteristics of straight tubular stents, particularly those used in arteries of the leg. Veryan’s stents have a helical shape that mimics the natural geometry of the human vascular system and provoke a swirling blood flow within the stented artery. They also reduce the incidence of kinking or fracture (a common problem in longer stents in limbs) as bending strains are distributed across the entire 3D stent geometry.

Market Opportunity

Veryan’s stents address unmet clinical need in restenosis, biomechanics and stent fracture in the treatment of peripheral arterial disease (PAD). A recent study showed over 200 million people worldwide live with PAD. Market for treatments is expected to reach $3.3 billion by 2017.

Veryan has already gained a CE Mark enabling sales of its BioMimics 3D™ stent within EEA. In July 2015 the company started a new study in the USA with the aim of securing FDA approval.

Chas Taylor - CEO

20+ years experience in medical devices. Founder of Mednova (sold to Abbott Laboratories). Former senior management roles at CR Bard

Veryan Medical
Our investment

% share holding

Carrying value

Imperial College London

Investment stage
post-Series A

Imperial Innovation news

Key milestones

  • January 2015

    Veryan Enters Into Distribution Agreement with Biosensors International for BioMimics 3D Stent

    Read more
  • January 2015

    Innovations leads £18m series B funding round in Veryan

    Read more
  • February 2014

    Two-year follow-up data shows that Veryan's helical geometry BioMimics 3D stent provides improvement in long-term patency when compared to straight nitinol stent

    Read more
  • November 2012

    Veryan receives CE Mark for its BioMimics 3D stent

    Read more
  • July 2012

    Completed enrolment of patients for its BioMimics 3D trial

  • July 2012

    Announced the appointment of medical device industry veterans Todd M. Pope and Jeffrey B. Jump as Non-executive directors

  • June 2012

    Appointment of Nick Yeo, formerly of Light Sciences, Inc., as Chief Operating Officer.

  • October 2011

    Raised £5m in a round co-led by Innovations and Seroba Kernel Life Sciences.

Imperial Innovations key people

Nigel Pitchford Nigel Pitchford
Nigel Pitchford Chief Investment Officer View profile
Inga Deakin Inga Deakin
Inga Deakin Associate Healthcare Ventures View profile